Onward Medical N.V. (ONWD.BR)
EUR 4.01
(-0.25%)
EUR 4.01
(-0.25%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -35.23 Million EUR | -12.61% |
| 2022 | -31.25 Million EUR | -10.48% |
| 2021 | -28.3 Million EUR | -85.18% |
| 2020 | -15.29 Million EUR | -45.04% |
| 2019 | -10.54 Million EUR | -29.01% |
| 2018 | -8.17 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -9.15 Million EUR | -10.54% |
| 2024 Q2 | -9.15 Million EUR | 0.0% |
| 2023 Q1 | -9.22 Million EUR | 47.93% |
| 2023 FY | - EUR | -12.72% |
| 2023 Q4 | -8.28 Million EUR | -1.08% |
| 2023 Q3 | -8.19 Million EUR | 57.71% |
| 2023 Q2 | -19.37 Million EUR | -110.06% |
| 2022 Q1 | -7.38 Million EUR | 20.98% |
| 2022 Q3 | -8.37 Million EUR | 46.72% |
| 2022 Q4 | -17.71 Million EUR | -111.47% |
| 2022 Q2 | -15.72 Million EUR | -113.05% |
| 2022 FY | - EUR | -10.48% |
| 2021 Q1 | -4.85 Million EUR | -10.04% |
| 2021 FY | - EUR | -85.18% |
| 2021 Q4 | -9.34 Million EUR | 0.0% |
| 2021 Q3 | -9.34 Million EUR | -92.58% |
| 2021 Q2 | -4.85 Million EUR | 0.0% |
| 2020 Q2 | -3.27 Million EUR | 0.0% |
| 2020 Q3 | -4.4 Million EUR | -34.44% |
| 2020 Q1 | -3.27 Million EUR | 0.0% |
| 2020 FY | - EUR | -45.04% |
| 2020 Q4 | -4.4 Million EUR | 0.0% |
| 2019 FY | - EUR | -29.01% |
| 2018 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Nicox S.A. | -16.23 Million EUR | -116.985% |
| European Medical Solutions | 59 Thousand EUR | 59818.644% |
| FERMENTALG | -10.51 Million EUR | -235.243% |
| argenx SE | -199.5 Million EUR | 82.339% |
| BioSenic S.A. | -6.79 Million EUR | -418.452% |
| Celyad Oncology SA | -7.76 Million EUR | -353.871% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | -135.207% |
| Oxurion NV | -16.72 Million EUR | -110.616% |
| PHAXIAM Therapeutics S.A. | -22.93 Million EUR | -53.659% |
| Financière de Tubize SA | 184.57 Thousand EUR | 19189.673% |
| UCB SA | 1.26 Billion EUR | 102.777% |